Forest Laboratories

Jeff Jonas joins Shire leadership team

Tuesday, November 20, 2012 11:51 AM

Irish specialty biopharmaceutical company Shire has appointed Jeff Jonas, MD, as president of Shire's regenerative medicine business.

More... »

Forest Labs, Adamas to develop fixed dose combo of Namenda XR and Donepezil for Alzheimer's

Wednesday, November 14, 2012 02:45 PM

Forest Laboratories, an international pharmaceutical company, and Adamas Pharmaceuticals, an Emeryville, Calif.-based therapeutics company focused on CNS disorders, have entered into an agreement for the development and commercialization of a fixed dosed combination (FDC) of Namenda XR (memantine HCl extended release) and donepezil HCl as a once daily therapy for the treatment of moderate to severe dementia of the Alzheimer's type in the U.S.

More... »

Forest Laboratories, moksha8 form strategic alliance for Latin America

Wednesday, October 24, 2012 10:33 AM

Forest Laboratories, an international pharmaceutical company, and moksha8, a pharmaceutical company that commercializes CNS medicines in Latin America, have entered into a broad strategic alliance that will provide Forest with a commercial footprint in Latin America and give moksha8 access to Viibryd and potentially other Forest products for the Latin American market.

More... »

Forest Labs and Nabriva to develop novel antibacterial agent

Friday, June 1, 2012 10:43 AM

Forest Laboratories, an international pharmaceutical manufacturer and marketer, and biotech Nabriva Therapeutics have entered into an agreement for the development of Nabriva’s novel antibacterial agent, BC-3781.

More... »

The CenterWatch Monthly, June 2012

Friday, June 1, 2012 09:00 AM

Western Europe sees drop in active investigators

More... »

Synthetic Biologics appoints Carol Reed as senior vice president

Thursday, May 17, 2012 11:12 AM

Synthetic Biologics, an Ann Arbor, Mich.-based developer of synthetic DNA-based therapeutics and disease-modifying medicines for serious illnesses, has appointed Carol Reed, M.D., as senior vice president of clinical & regulatory affairs.

More... »

Rosenberg joins Esperion Therapeutics as CMO

Monday, April 9, 2012 02:56 PM

Esperion Therapeutics, a Plythmouth, Michigan-based company that discovers and develops novel therapies for the treatment of cardiovascular and metabolic diseases, has appointed Noah Rosenberg, MD, as its chief medical officer.

More... »

ImmusanT names Patrick Griffin as chief medical officer, senior VP

Monday, March 19, 2012 12:37 PM

ImmusanT, a privately-held biotech based in Cambridge, Mass., has named Patrick H. Griffin, MD, as chief medical officer and senior vice president of development.

More... »

Positive phase III results with investigational antipsychotic Cariprazine

Friday, February 10, 2012 11:52 AM

Forest Laboratories and Gedeon Richter have released preliminary top-line results from a phase III clinical trial of cariprazine (RGH-188), an investigational antipsychotic agent, in patients with acute mania associated with bipolar I disorder.

More... »

Mersana Therapeutics appoints Michael A. Metzger as executive VP, COO

Wednesday, April 20, 2011 11:46 AM

Michael A. Metzger has joined Mersana Therapeutics, a platform-based cancer therapeutics company, as executive vice president & chief operating officer. 

More... »